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Introduction: Hypoxia-inducible factor-2α (also called endothelial 
periodic acid–Schiff domain protein 1 [EPAS1]) seems to play an 
important role in some carcinogenesis, though there is no informa-
tion on the relationship between single nucleotide polymorphism of 
EPAS1 and lung cancer development. The aim of this study was to 
explore a possible association of the EPAS1 gene rs4953354 poly-
morphism with susceptibility to lung cancer.
Methods: A case–control study of 346 patients with non–small-
cell lung carcinoma (adenocarcinoma = 249, squamous cell carci-
noma = 97) and 247 healthy control subjects was carried out. A/G 
polymorphism within an intron 2 of the EPAS1 (rs4953354) was 
determined by direct sequencing.
Results: A frequency of lung adenocarcinoma patients with a minor 
allele G (A/G or G/G genotype) at the rs4953354 was much higher 
than that of controls (odds ratio, 1.800; 95% confidence interval, 
1.161–2.791; p = 0.008). This association was more evident when 
analyzed using female never-smokers (odds ratio, 3.31; 95% con-
fidence interval, 1.21–9.01; p = 0.017). Mutations in epidermal 
growth factor receptor tended to be frequent in patients with G allele 
at the rs4953354, compared with those with other genotypes.
Conclusion: The EPAS1 rs4953354 may be a potentially suscepti-
ble marker for development of lung adenocarcinoma, especially in 
female never-smokers.
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(J Thorac Oncol. 2014;9: 1709–1713)
Evaluation of the genetic factors underlying the develop-ment of lung cancer can elucidate the etiology of the dis-
ease and identify high-risk individuals for targeted screening 
and/or prevention.
The transcription factor hypoxia-inducible factor-α 
(HIF-α) plays an important role in the regulation of hypoxic 
signaling. It has also been reported to be involved in the pro-
gression of solid tumors and associated with various aspects 
of carcinogenesis, including tumor metabolism, angiogenesis, 
and metastasis.1 Although HIF-1α and HIF-2α (also called 
endothelial periodic acid–Schiff domain protein 1 [EPAS1]) 
have similar functions in vitro, several recent in vivo stud-
ies on the pathophysiological roles of HIF-2α have described 
its role in angiogenesis during human fetal lung development, 
especially in the last phases of pregnancy, preparing the fetus 
for extrauterine life.2,3 In addition, high expression of HIF-
2α is reported to be associated with poor outcome in various 
cancers, including lung cancer.4 Several groups have recently 
reported associations of polymorphisms (SNPs) of HIF-2α 
gene (EPAS1) with the development of renal cell carcinoma5 
and prostate cancer.6 However in SNPs, whether HIF-2α is 
involved in the lung carcinogenesis remains elusive at present.
In the present study, we focused on the EPAS1 (HIF-2α) 
gene rs4953354 polymorphism that has been reported to contrib-
ute to adaptation to high-altitude hypoxia in Sherpas.7 We con-
ducted a case–control study to explore a possible association of 
the rs4953354 polymorphism with susceptibility to non–small-
cell lung cancer in Japanese population, with a special emphasis 
on adenocarcinoma developed among female never-smokers.
PATIENTS AND METHODS
Study Subjects
The study subjects were 593 individuals, including 346 
patients with lung cancer and 247 healthy control subjects. The 
patient group included 249 patients with lung adenocarcinoma 
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University Hospital, Higashihiroshima Medical Center, and 
Hiroshima University Hospital, between 2009 and 2012. The 
healthy control subjects were randomly selected from sub-
jects who received annual health screening at the Shimane 
Institute of Health Science and Hiroshima University Faculty 
of Medicine between 2009 and 2012. The smoking status was 
obtained from a self-administered questionnaire that focused 
on cigarette smoking history, and the subjects were divided into 
never-smokers, ever-smokers, including present- and ex-smok-
ers, and those having undetermined smoking history. Table 1 
lists the clinicopathological features of the patient group and 
anthropometric features of the control group. Each participant 
provided written informed consent for the collection of blood 
and/or tissue samples and subsequent analysis. Ethical approval 
was obtained from the Institutional Review Board of Shimane 
University Faculty of Medicine, Higashihiroshima Medical 
Center, and Hiroshima University Faculty of Medicine.
DNA Extraction, Genotyping, 
and Mutation Analysis
Genomic DNA was isolated from peripheral total blood 
cells or surgically resected normal tissues adjacent to cancers 
using NucleoSpin Blood or Tissue (MACHEREY-NAGEL, 
Düren, Germany) according to the instructions provided by 
the manufacturer. Polymerase chain reaction was performed to 
amplify the human EPAS1 gene using specific primer set and 
conditions. The following primer set was used to amplify a 281-
base pair fragment of the EPAS1, which contains polymorphic 
allele A/G (rs4953354): forward 5′-CTG GGA AAG AGG GAA 
TCC AGT GTG3′ and reverse 5′-CTC AGC CCA CTG TTC 
TCT CTT TGC-3′. The polymerase chain reaction conditions 
were 40 cycles of denaturation at 95°C for 30 seconds, anneal-
ing at 63°C for 30 seconds and extension at 68°C for 30 seconds. 
Direct sequence analysis was carried out using these primers 
with Big Dye Terminator Cycle Sequencing Kit and ABI PRISM 
310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Statistical Analysis
All the statistical analyses were conducted, unless other-
wise specified, using JMP 9.0.3 (SAS Institute, Cary, NC). We 
used the statistical language and environment R for calcula-
tion of extended Fisher’s exact test for 2 × 3 tables.8 p values 
less than 0.05 were considered statistically significant.
RESULTS
Association of EPAS1 rs4953354 
Polymorphism with Lung Cancer
The control subjects were slightly younger than the 
patients, while no difference was observed for gender distri-
bution and smoking status (Table 1). The distribution of A/G 
alleles at rs4953354 among the control subjects fulfilled the 
Hardy–Weinberg equilibrium (Table 2).
We then stratified the patient group by histopathology 
and examined an association between the polymorphism and 
each lung cancer type. We found a statistically significant 
association between the rs4953354 and susceptibility to lung 
adenocarcinoma: The proportion of adenocarcinoma patients 
with at least one G allele was much higher than that of the con-
trol subjects (odds ratio [OR], 1.607; 95% confidence interval 
[95% CI], 1.039–2.484; p = 0.032). In addition, the frequency 
of G allele was much higher in adenocarcinoma patients 
than the control subjects (OR, 1.632; 95% CI, 1.097–2.428; 
p = 0.015). However, no such association was found for squa-
mous cell carcinoma (Table 2).
Association of Adenocarcinoma with the SNP 
(rs4953354) According to Smoking Status
As genesis of lung adenocarcinoma differed between 
smokers and nonsmokers, we analyzed an association of the 
rs4953354 SNP and lung adenocarcinoma development by 
smoking status. The proportion of patients who were never-
smokers and had at least one G allele was significantly higher 
than never-smoker control subjects (OR, 2.40; 95% CI, 1.08–
5.36; p = 0.030). In addition, the frequency of the G allele among 
never-smoker patients was much higher than never-smoker con-
trol subjects (OR, 2.29; 95% CI, 1.12–4.65; p = 0.020).
Association of Adenocarcinoma with 
the SNP in Female Never-Smokers
Recently, lung adenocarcinoma developed in female 
non-smokers of eastern Asian countries attracted attention. 
We analyzed the association of the SNP and the adenocarci-
noma susceptibility by gender. A statistically significant asso-
ciation was found in women (OR, 2.31; 95% CI, 1.00–5.33; 
P = 0.046, Table 3), but not in men. The same association 
was confirmed even after adjustment for smoking status and 
age: Genotype with at least one G allele showed a statistically 
significant association (adjusted OR, 3.868; 95% CI, 1.381–
12.078; p = 0.009; Table 3).
We next analyzed the association only in female never-
smokers and also found a statistically significant association 
TABLE 1.  Clinical Characteristics of Patients and Control 
Subjects
Control Case p Value
Age (yr), mean ± SD 64.0 ± 13.0 67.3 ± 10.1 0.0009a
Gender
  Males (n) 195 263 0.078b
  Females (n) 52 83
Smoking status
  Never-smoker (n) 71 62 0.57b
  Ever-smoker (n) 168 212
  No information (n) 8 72
Histopathology
  Adenocarcinoma (n) 249
  Squamous cell carcinoma (n) 97
EGFR mutation status
  Wild (n) 210
  Mutated (n) 54
  No data available (n) 82
aWelch’s t test.
bPearson’s χ2 test.
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TABLE 2.  Distribution of EPAS1 rs4953354 Polymorphism in Patients and Control Subjects
rs4953354 Control Case Odds Ratio (95% CI) p Value
All lung cancer A/A (n) 204 267 0.174a
A/G (n) 41 71 0.068b
G/G (n) 2 8
A/A (n) 204 267 0.107c
A/G or G/G (n) 43 79
A allele (n) 449 605 0.062c
G allele (n) 45 87
Adenocarcinoma A/A (n) 204 186 0.054a
A/G (n) 41 56 0.017b
G/G (n) 2 7
A/A (n) 204 166 1.800 (1.161–2.791) 0.008c
A/G or G/G (n) 43 63
A allele (n) 449 428 1.632 (1.097–2.428) 0.015c
G allele (n) 45 70
Squamous cell carcinoma A/A (n) 204 81 0.944a
A/G (n) 41 15 0.887b
G/G (n) 2 1
A/A (n) 204 81 0.937 (0.500–1.758) 0.840c
A/G or G/G (n) 43 16
A allele (n) 449 177 0.958 (0.534–1.719) 0.887c
G allele (n) 45 17
aExtended Fisher’s exact test.




Sex rs4953354 Control Case OR 95% CI p Value
Adjusted OR  
(95% CI)e p Value
Males A/A (n) 162 137 0.186a
A/G (n) 32 31 0.174b
G/G (n) 1 5
A/A (n) 162 137 1.29 (0.76–2.18) 0.340c 1.255 (0.721–2.180) 0.421d
A/G or G/G (n) 33 36
A allele (n) 356 305 1.41 (0.87–2.27) 0.161c
G allele (n) 34 41
Females A/A (n) 42 49 0.123a
A/G (n) 9 25 0.065b
G/G (n) 1 2
A/A (n) 42 49 2.31 (1.00–5.33) 0.046c 3.868 (1.381–12.078) 0.0094d
A/G or G/G (n) 10 27
A allele (n) 93 123 1.99 (0.95–4.20) 0.066c
G allele (n) 11 29
aExtended Fisher’s exact test.
bCochran–Armitage test for trend.
cPearson’s χ2 test.
dLogistic regression analysis.
eAdjusted for age and smoking status.
CI, confidence interval; OR, odds ratio.
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(OR, 3.31; 95% CI, 1.21–9.01; p = 0.017); the frequency of 
G allele was significantly higher in the patient group than 
the control group (OR, 2.71; 95% CI, 1.12–6.53; p = 0.023, 
Table 4). However, no such association was observed in men 
(Table 3).
Association of the SNP with EGFR Somatic 
Mutation in Adenocarcinoma
EGFR mutation is often found in lung adenocarcinoma 
in female non-smokers. We then investigated the association 
of the SNP with EGFR mutation status in 218 lung adenocar-
cinoma patients. The proportion of patients with at least one G 
allele tended to be higher in those with EGFR mutations than 
those with A/A homozygote (OR, 1.89; 95% CI, 0.96–3.68; 
p = 0.061, Table 5).
DISCUSSION
To the best of our knowledge, this is the first study 
that identified a potential genetic susceptible to lung 
adenocarcinoma in female never-smokers. We found that 
the G allele at the rs4953354 locus of EPAS1 polymorphism 
was associated with an elevated risk of lung adenocarcinoma 
in female never-smokers. Lung cancer developed among 
never-smokers represents a unique subset of the cancer. 
Approximately 10% to 15% of lung cancers are diagnosed 
in never-smokers.9 Accumulating evidences suggest that lung 
cancer developed from never-smokers is a distinct disease, 
with a different etiology and natural history from the one 
developed from smokers.10 Although the mechanisms under-
lying the high risk was not determined, EPAS1 (HIF-2α) may 
contribute to lung carcinogenesis through the HIF signaling 
pathway, such as antiapoptosis, tumor angiogenesis, modified 
energy metabolism, and genomic instability.1 Interestingly, 
our results showed that the frequency of adenocarcinoma 
patients with at least one G allele tended to be higher in those 
with EGFR mutations. Although there is no report examin-
ing the relationship between EGFR mutations and HIF-2α, a 
positive regulatory loop between EGFR and HIF signals may 
exist.11 Putra et al12 suggested that variant alleles of HIF1A 
enhanced HIF-1α functions, including its inhibitory effect 
on the DNA repair system, resulting in genomic instability 
and increased mutation of tumor suppressor genes. Database 
analysis showed that the rs4953354 is located close to the 
binding sites of several transcription factors, as identified 
by the chromatin immunoprecipitation sequence, suggest-
ing that the SNP might affect EPAS1 expression. Altered 
EPAS1 activity by the G allele at the rs4953354 might be 
involved in not only activated HIF signals but also induced 
EGFR mutations, which could increase the susceptibility to 
lung adenocarcinoma. Thus, our study identified a potentially 
useful biomarker for high-risk individuals, i.e., female never-
smokers, for lung adenocarcinoma. The results also enhance 
our understanding of the molecular mechanisms of lung car-
cinogenesis in such patients.
Our study has some limitations. Because the majority of 
the control subjects were recruited from annual health exami-
nations, the mean age of control subjects was slightly younger 
than that of the patients and a detailed smoking history of 
control subjects such as Brinkman index was not available. 
Furthermore, the number of female never-smokers with lung 
adenocarcinoma was relatively small. To verify the relation-
ship between the SNP and EGFR mutation, recruitment of 
a larger number of lung adenocarcinoma patients in female 
never-smokers will absolutely be needed.
CONCLUSION
In conclusion, the present study identified a potential 
risk factor for lung adenocarcinoma in female never-smokers. 
A future study with a large scale is required to confirm the 
observation.
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TABLE 4.  Relation between Adenocarcinoma and EPAS1 
rs4953354 Polymorphism among Female Never-Smokers
rs4953354 Control Case
Odds Ratio  
(95% CI) p Value
A/A (n) 36 28 0.035a
A/G (n) 6 16 0.028b
G/G (n) 1 2
A/A (n) 36 28 3.31 (1.21–9.01) 0.017c
A/G or G/G (n) 7 18
A allele (n) 78 72 2.71 (1.12–6.53) 0.023c
G allele (n) 8 20
aExtended Fisher’s exact test.
















A/A (n) 127 32 0.081a
A/G (n) 34 18 0.164b
G/G (n) 6 1
A/A (n) 127 32 1.89  
(0.96–3.68)
0.061c 2.092  
(0.936–4.640)
0.072d
A/G or G/G (n) 40 19
A allele (n) 288 82 1.53  
(0.86–2.73)
0.15
G allele (n) 46 20
aExtended Fisher’s exact test.
bCochran–Armitage test for trend.
cPearson’s χ2 test.
dLogistic regression analysis.
eAdjusted for age and smoking status.
CI, confidence interval; OR, odds ratio.
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